WebFeb 25, 2024 · Active Comparator: Arm A: DVRd + ASCT+DVRd (Standard Therapy) Participants will receive daratumumab, bortezomib, lenalidomide and dexamethasone … WebMay 20, 2024 · In the D-VTd arm, infusion-related reactions occurred in 35.4% of pts. Conclusions: D-VTd in induction prior to and consolidation after ASCT improved depth of response (sCR, ≥CR, and MRD...
D-VTd in induction prior to and consolidation after ASCT
WebIn the first part of the study, patients were randomized to receive induction treatment with VTd alone or in combination with DARZALEX ... (DVTd): The most frequent adverse reactions (≥20%) were infusion reactions (35%), nausea (30%), upper respiratory tract infection (27%), pyrexia (26%), and bronchitis (20%). Serious adverse reactions (≥2 ... palpito serie ver completa
New treatment for myeloma approved in England and Wales
WebSep 27, 2024 · Treatment with DVTd resulted in a reduction in the risk of progression or death by 53 percent compared to VTd alone (HR=0.47; 95 percent CI: 0.33, 0.67; p<0.0001).The sCR rate at Day 100 post-ASCT was 28.9 percent in the DVTd arm and 20.3 percent in the VTd arm. Adverse reactions with daratumumab WebDVTd versus VTd – In another trial (CASSIOPEIA), 1085 patients with newly diagnosed MM eligible for HCT were randomly assigned to receive induction with four cycles of bortezomib, thalidomide, and dexamethasone with or without daratumumab (DVTd versus VTd), followed by autologous HCT plus two cycles of consolidation with the assigned … WebAug 3, 2024 · Standard Induction for Newly Diagnosed Symptomatic Myeloma EP: 3. High-Risk Multiple Myeloma: Selecting Initial Therapy EP: 4. Improving Maintenance Therapy … palpiturfe